Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Pre-Submission Meetings Being Considered By FDA

Executive Summary

Designed to boost application quality, creating such meetings would be another sign of the evolution of the Office of Generic Drugs.

Advertisement

Related Content

CDER’s Sequestration Strategy Aided By 400 Missing FTEs
Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
FDA Generics Director’s Departure Shows Why Chemistry Matters
Outgoing OGD Director Outlines Accomplishments During His Tenure
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
ANDA Complete Response Letters To Become Routine In 2012

Topics

Advertisement
UsernamePublicRestriction

Register

PS055415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel